Response to microtubule-interacting agents in primary epithelial ovarian cancer cells

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Pellicciotta, Ilenia ^a   Yang, Chia Ping H ^b   Venditti, Charis A ^c   Goldberg, Gary L ^b   Shahabi, Shohreh ^b,c  

^a NEW YORK UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c DANBURY HOSPITAL   (United States)

Author keywords

Cell cycle analyses; Chemosensitivity; Epothilone B; Microtubule interacting agents; Primary ovarian cancer cells

Indexed keywords

ALPHA TUBULIN; ARGININE; BETA TUBULIN; DISCODERMOLIDE; EPOTHILONE B; PACLITAXEL; PROLINE; PROTEIN P53;

ARTICLE; ASCITES FLUID; CANCER PATIENT; CANCER RESISTANCE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE M PHASE; CELL IMMORTALIZATION; CELL KINETICS; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG SENSITIVITY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GENE MUTATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OVARY CARCINOMA; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 84875951356     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-33     Document Type: Article

References (38)

1. Alama A, Barbieri F, Favre A, Cagnoli M, Noviello E, Pedulla F, Viale M, Foglia G, Ragni N. Establishment and characterization of three new cell lines derived from the ascites of human ovarian carcinomas. Gynecol Oncol 1996, 62:82-88. 10.1006/gyno.1996.0194, 8690298.
2. Yuan Y, Kim WH, Han HS, Lee JH, Park HS, Chung JK, Kang SB, Park JG. Establishment and characterization of human ovarian carcinoma cell lines. Gynecol Oncol 1997, 66:378-387. 10.1006/gyno.1997.4785, 9299249.
3. Yamada K, Tachibana T, Hashimoto H, Suzuki K, Yanagida S, Endoh H, Kimura E, Yasuda M, Tanaka T, Ishikawa H. Establishment and characterization of cell lines derived from serous adenocarcinoma (JHOS-2) and clear cell adenocarcinoma (JHOC-5. JHOC-6) of human ovary. Hum Cell 1999, 12:131-138.
4. Hill BT, Whelan RD, Gibby EM, Sheer D, Hosking LK, Shellard SA, Rupniak HT. Establishment and characterization of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. Int J Cancer 1987, 39:219-225. 10.1002/ijc.2910390216, 3804493.
5. Martello LA, McDaid HM, Regl DL, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000, 6:1978-1987.
6. Lavarino C, Pilotti S, Oggionni M. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000, 18:3936-3945.
7. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253:49-53. 10.1126/science.1905840, 1905840.
8. Gross E, Kiechle M, Arnold N. Mutation analysis of p53 in ovarian tumors by DHPLC. J Biochem Biophys Methods 2001, 47:73-81. 10.1016/S0165-022X(00)00153-6, 11179763.
9. McManus DT, Murphy M, Arthur K, Hamilton PW, Russell SE, Toner PG. p53 mutation, allele loss on chromosome 17p, and DNA content in ovarian carcinoma. J Pathol 1996, 179:177-182. 10.1002/(SICI)1096-9896(199606)179:2<177::AID-PATH561>3.0.CO;2-2, 8758210.
10. Righetti SC, Della Torre G, Pilotti S, Ménard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Böhm S, Bresciani GL, Spatti G, Zunino F. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996, 56:689-693.
11. Papadakis EN, Dokianakis DN, Spandidos DA. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000, 3:389-392. 10.1006/mcbr.2000.0241, 11032762.
12. Dumont P, Leu JI, Della Pietra AC, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33(3):357-365. Epub 2003 Feb 3, 10.1038/ng1093, 12567188.
13. Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004, 108:196-199. 10.1002/ijc.11548, 14639602.
14. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nicons J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WGJ. A common polymorphism acts as an intragenic modifier of mutant p53 behavior. Nat Genet 2000, 25:47-54. 10.1038/75586, 10802655.
15. Vikhanskaya F, Siddique MM, Kei Lee M, Broggini M, Sabapathy K. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs. Clin Cancer Res 2005, 11:4348-4356. 10.1158/1078-0432.CCR-04-1547, 15958617.
16. Sjalander A, Birgander R, Kivela A, Beckman G. p53 polymorphisms and haplotypes in different ethnic groups. Hum Hered 1995, 45:144-149. 10.1159/000154275, 7615299.
17. Sullivan A, Syed N, Gasco M, Bergamaschi D, Trigiante G, Attard M, Hiller L, Farrell PJ, Smith P, Lu X, Crook T. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004, 23:3328-3337. 10.1038/sj.onc.1207428, 15077186.
18. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller-Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 2005, 11:8372-83. 10.1158/1078-0432.CCR-05-0899, 16322298.
19. Kuroda Y, Tsukino H, Nakao H, Imai H, Katoh T. p53 Codon 72 polymorphism and urothelial cancer risk. Cancer Lett 2003, 189:77-83. 10.1016/S0304-3835(02)00518-9, 12445680.
20. Granja F, Morari J, Morari EC, Correa LA, Assumpcao LV, Ward LS. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett 2004, 210:151-157. 10.1016/j.canlet.2004.01.016, 15183530.
21. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutierrez-Enriquez S, Hall J, Guino E, Peinado MA, Capella G, Canzian F. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004, 23:1954-1956. 10.1038/sj.onc.1207305, 14647431.
22. Bergamaschi G, Merante S, Orlandi E, Galli A, Bernasconi P, Cazzola M. TP53 codon 72 polymorphism in patients with chronic myeloid leukemia. Haematologica 2004, 89:868-869.
23. Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer 2002, 87:1013-1018. 10.1038/sj.bjc.6600595, 2364333, 12434294.
24. Bonafe M, Ceccarelli C, Farabegoli F, Santini D, Taffurelli M, Barbi C, Marzi E, Trapassi C, Storci G, Olivieri F, Franceschi C. Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients. Clin Cancer Res 2003, 9:4860-4864.
25. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998, 393:229-234. 10.1038/30400, 9607760.
26. He L, Yang CP, Horwitz SB. Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 2001, 1:3-10.
27. Schibler MJ, Cabral F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α- and β-tubulin. J Cell Biol 1986, 102:1522-1531. 10.1083/jcb.102.4.1522, 2114175, 2870070.
28. Goncalves A, Braguer D, Kamath K. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001, 98:11737-11741. 10.1073/pnas.191388598, 58799, 11562465.
29. Martello LA, Verdier-Pinard P, Shen HJ. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an α-tubulin mutation. Cancer Res 2003, 63:1207-1213.
30. Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in α- and β-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther 2003, 2:597-605.
31. Poruchynsky MS, Kim JH, Nogales E. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in α- or β-tubulin and increased microtubule stability. Biochemistry 2004, 43:13944-13954. 10.1021/bi049300+, 15518543.
32. Yvon AM, Wadsworth P, Jordan MA. Taxol suppresses dynamics of individual microtubules in living human tumor cells. Mol Biol Cell 1999, 10:947-959. 10.1091/mbc.10.4.947, 25218, 10198049.
33. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003, 22:7280-7295. 10.1038/sj.onc.1206934, 14576838.
34. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997, 272:17118-17125. 10.1074/jbc.272.27.17118, 9202030.
35. Xia S, Kenesky CS, Rucker PV, Smith AB, Orr GA, Horwitz SB. A photoaffinity analogue of discodermolide specifically labels a peptide in beta-tubulin. Biochemistry 2006, 45:11762-11775. 10.1021/bi060497a, 17002277.
36. Finlay GJ, Baguley BC, Wilson WR. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 1984, 139:272-277. 10.1016/0003-2697(84)90002-2, 6476363.
37. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988, 48:589-601.
38. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes. J Clin Invest 1997, 100:1282-1293. 10.1172/JCI119642, 508306, 9276747.